1. Home
  2. NWGL vs BCAB Comparison

NWGL vs BCAB Comparison

Compare NWGL & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nature Wood Group Limited

NWGL

Nature Wood Group Limited

HOLD

Current Price

$1.33

Market Cap

19.6M

Sector

N/A

ML Signal

HOLD

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$0.20

Market Cap

20.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWGL
BCAB
Founded
2008
2007
Country
Macau
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.6M
20.8M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
NWGL
BCAB
Price
$1.33
$0.20
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$1.00
AVG Volume (30 Days)
36.0K
3.2M
Earning Date
12-29-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,648,931.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$0.14
52 Week High
$6.61
$1.43

Technical Indicators

Market Signals
Indicator
NWGL
BCAB
Relative Strength Index (RSI) 49.57 28.51
Support Level $1.21 $0.14
Resistance Level $1.45 $0.39
Average True Range (ATR) 0.11 0.05
MACD 0.01 0.00
Stochastic Oscillator 48.72 25.27

Price Performance

Historical Comparison
NWGL
BCAB

About NWGL Nature Wood Group Limited

CL Workshop Group Ltd, formerly Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber, recycled charcoal, synthesized charcoal, machine-made charcoal, and essential oils. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Share on Social Networks: